Stevenson Search Partners is pleased to announce the appointment of Dr. Susan Altschuller as Chief Financial Officer for Dragonfly Therapeutics.
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing novel therapies that harness the body's immune system to bring breakthrough treatments to patients. The organization’s mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes.
Dr. Altschuller is a seasoned senior biopharma executive with more than two decades of strategic and financial leadership experience at leading pharmaceutical and biotechnology companies. Most recently, she served as the chief financial officer of Cerevel Therapeutics, a biotechnology company developing therapies for neuroscience diseases, until its acquisition by AbbVie earlier this month.
